Clinimetría y desarrollo tecnológico en ejercicio terapéutico
CLIDET
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (5)
2023
-
Which people with diabetes are treated with a disposable, half-unit insulin pen? A real-world, retrospective, database study in Spain
Endocrinology, Diabetes and Metabolism, Vol. 6, Núm. 6
2021
-
Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers
Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 8, pp. 557-566
2017
-
Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
International Journal of General Medicine, Vol. 10, pp. 23-26
2016
-
Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2
Endocrinologia y Nutricion, Vol. 63, Núm. 10, pp. 519-526
2013
-
Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with Type2 diabetes: An open-label randomized trial
Diabetic Medicine, Vol. 30, Núm. 1, pp. 109-113